Tuesday, October 10, 2017

Scythian Biosciences Corp.’s (TSXV: $SCYB.V) Professional Athlete Advisory Committee Head, NFL Star Bart Oates says, “Company has a winning team”

Scythian Biosciences Corp.’s (TSXV: $SCYB.V) Professional Athlete Advisory Committee Head, NFL Star Bart Oates says, “Company has a winning team”



October 10, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with NFL Champion Bart Oates, the first appointment of  the Scythian Biosciences  (TSX.V: SCYB) Professional Athlete Advisory Committee.

Oates, a five-time NFL Pro Bowl player and three-time Super Bowl Champion, was announced as the first appointee to the newly formed committee on October 2. Oates identified the strength of the team in all areas as a guide to why Scythian will be successful.

He also shares his personal experiences with concussions in the NFL and his education of the company’s treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination and how it can make a difference going forward.


Hear the full podcast: 

About Mr. Oates

A former center for the New York Giants and San Francisco 49ers, Bart Oates is a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion. Once finished with football, Mr. Oates took law classes and then worked as an attorney, receiving his law degree from Seton Hall University. Mr. Oates maintains an active role in many services to the community, including serving as President of the NY/NJ Chapter of the NFL Alumni Association.

Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.


About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Stitcher. Spreaker.com, iHeart.com Radio  and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp


Contact Investorideas.com
800-665-0411

Monday, October 2, 2017

Scythian Biosciences Corp. (TSXV: $SCYB.V) Announces Bart Oates, 5-time #NFL Pro Bowl player and a 3-time Super Bowl Champion Joins Professional Athlete Advisory Committee

TORONTO - October 2, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) announces the formation of its Professional Athlete Advisory Committee and the first appointment ,with Bart Oates, a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion joining the new Committee. The purpose of this committee is to bring together various, current, and former pro-athletes who have experienced or share concern for the pain and suffering associated with concussions that occur during sports competitions.
"The member's intimate knowledge and personal experience will lend Scythian and our research partners at the University of Miami great insight into the world of sports and the aftermath of head injuries. Bart Oates, who has been an Advisory Board member will head up this committee and lead in recruiting new inductees from Professional Football, Hockey, Basketball, Boxing, Soccer and more," commented Mr. Jonathan Gilbert, CEO of the Company.
About Mr. Oates
A former center for the New York Giants and San Francisco 49ers, Bart Oates is a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion. Once finished with football, Mr. Oates took law classes and then worked as an attorney, receiving his law degree from Seton Hall University. Mr. Oates maintains an active role in many services to the community, including serving as President of the NY/NJ Chapter of the NFL Alumni Association.
Stock Options
The Company has also issued 62,500 incentive stock options to an officer and advisors of the Company entitling the grantees to purchase up to 62,500 common shares of the Company at an exercise price of $8.00 per share for a period of five years. The options are subject to certain vesting provisions and are subject to regulatory approval.
About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities
Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.
Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including the risk factors discussed in the Filing Statement and the registration statement which are incorporated herein by reference and are available through SEDAR at www.sedar.com and on the SEC EDGAR filing service at www.sec.gov. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
For further information, please contact:
Scythian Biosciences Corp.
Jonathan Gilbert
CEO
Phone: (212) 729-9208
Email: info@scythianbio.com

Scythian Biosciences Corp. (TSX.V: SCYB)

is a Featured biotech and marijuana company on Investorideas.com
Visit Profile page: http://www.investorideas.com/CO/SCYB/
Get News Alerts on Scythian Biosciences Corp.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Friday, September 8, 2017

#SPORTS, #DEFENSE, #TECH #STOCKS ADDED TO #INVESTORIDEAS.COM #STOCK LISTS

#SPORTS, #DEFENSE, #TECH  #STOCKS ADDED TO #INVESTORIDEAS.COM #STOCK LISTS



Point Roberts, WA, Delta BC – September 8, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories in tech, defense, and sports/sporting.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listings for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

Read this news in full at
  
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 14 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Tuesday, September 5, 2017

Scythian Biosciences Corp. (TSXV: $SCYB.V) Appoints Chief Scientific Officer

Scythian Biosciences Corp. (TSXV: $SCYB.V) Appoints Chief Scientific Officer



TORONTO - September 5, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) is pleased to announce that Maghsoud Dariani has become the Chief Scientific Officer of the Company. Mr. Dariani was previously on the Company's advisory board and has over 35 years of experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani's experience includes, among other things, management positions at Semorex, Focus Pharmaceuticals, Celgene and Chiral Pharmaceuticals.

Read this news in full at

About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Wednesday, August 30, 2017

Scythian Biosciences Corp. (TSXV: $SCYB.V) Applies for Listing of Common Stock on NASDAQ

Scythian Biosciences Corp. (TSXV: $SCYB.V) Applies for Listing of Common Stock on NASDAQ



TORONTO - August 30, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (TSXV: SCYB) (the "Company") is pleased to announce that it has submitted an initial listing application to list its common shares on the NASDAQ Capital Market.

The Company's common shares have traded on the TSX Venture Exchange (the "TSXV") under the symbol "SCYB" since August 8, 2017.

Read this news in full at

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp


Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Tuesday, August 29, 2017

Concussion and TBI Treatment Company Scythian Biosciences (TSX.V: $SCYB.V) Retains The Weinberg Group for FDA IND and IND Consulting Services

Concussion and TBI Treatment Company Scythian Biosciences (TSX.V: $SCYB.V) Retains The Weinberg Group for FDA IND and IND Consulting Services



TORONTO - August 29, 2017 (Investorideas.com Newswire)   FDA news - Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) reports  it has entered into a consulting arrangement with The Weinberg Group and has retained The Weinberg Group's services for assistance with the Company's FDA application process, including pre-IND and IND consulting services.

Read this news in full at

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country